A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

© The Author(s). 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,...

Full description

Bibliographic Details
Main Author: Coelho, Teresa (author)
Other Authors: Adams, David (author), Conceição, isabel (author), Waddington-Cruz, Márcia (author), Schmidt, Hartmut H. (author), Buades, Juan (author), Campistol, Josep (author), Berk, John L. (author), Polydefkis, Michael (author), Wang, Jing Jing (author), Chen, Jihong (author), Sweetser, Marianne T. (author), Gollob, Jared (author), Suhr, Ole B. (author)
Format: article
Language:eng
Published: 2021
Subjects:
ATTR amyloidosis
Cardiomyopathy
Patisiran
Polyneuropathy
NA interference
Online Access:http://hdl.handle.net/10451/48439
Country:Portugal
Oai:oai:repositorio.ul.pt:10451/48439

Internet

http://hdl.handle.net/10451/48439

Similar Items